Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(3.66)
# 780
Out of 4,967 analysts
20
Total ratings
45%
Success rate
12.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.45 | +562.25% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.82 | +265.01% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $1.91 | +214.14% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $10.10 | +58.49% | 4 | Aug 12, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $31 → $12 | $6.33 | +89.57% | 2 | Jul 14, 2025 | |
| VRNA Verona Pharma | Reiterates: Buy | $92 → $116 | $106.10 | +9.33% | 2 | Jun 18, 2025 | |
| PYPD PolyPid | Maintains: Buy | $12 → $9 | $3.41 | +163.93% | 2 | Jun 18, 2025 | |
| CING Cingulate | Maintains: Buy | $12 → $11 | $3.73 | +194.91% | 2 | May 19, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $5.39 | +438.53% | 1 | Dec 5, 2024 |
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.45
Upside: +562.25%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.82
Upside: +265.01%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.91
Upside: +214.14%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $10.10
Upside: +58.49%
Capricor Therapeutics
Jul 14, 2025
Maintains: Buy
Price Target: $31 → $12
Current: $6.33
Upside: +89.57%
Verona Pharma
Jun 18, 2025
Reiterates: Buy
Price Target: $92 → $116
Current: $106.10
Upside: +9.33%
PolyPid
Jun 18, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.41
Upside: +163.93%
Cingulate
May 19, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $3.73
Upside: +194.91%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $5.39
Upside: +438.53%